 |
|
|
| |
The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232
|
| |
| |
GLASGOW:
HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16)
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Safety Analysis - (11/02/16)
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16)
Pharm Wk: Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-17, 2017, Chicago
Magee M1, Sevinsky H2, Ackerman P3, Tendolkar A4, Lubin S4, Myers E4, Wu W5, Llamoso C3, Eley T5
1Glaxosmithkline, King Of Prussia, United States; 2ViiV Healthcare, Upper Providence, USA; 3ViiV Healthcare, Wallingford, USA; 4Bristol-Myers Squibb, Hopewell, USA; 5Bristol-Myers Squibb, Lawrenceville, USA
|
| |
|
|
|
|
|
